Evidence map›Paper›PMID 20390032›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2010

Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

M Kernt, A Kampik

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 75 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 2 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04212078 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Intracameral Levofloxacin (0.5%) Versus Intracameral Cefuroxime (1mg/0.1ml) Effect on Corneal Endothelial Cell Count and Morphology in Uneventful Phacoemulsification

TypeinterventionalSponsorNational University of MalaysiaRan2019 to 2022Enrolled138ConditionsEndophthalmitis PostoperativeArmsLevofloxacin Ophthalmic, Cefuroxime
NCT04212429 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

The Clinical Safety of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

TypeinterventionalSponsorNational University of MalaysiaRan2019 to 2022Enrolled128ConditionsEndophthalmitis PostoperativeArmsLevofloxacin Ophthalmic Product, Moxifloxacin Ophthalmic Solution
NCT04214821 phase1 / phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

TypeinterventionalSponsorNational University of MalaysiaRan2019 to 2022Enrolled128ConditionsEndophthalmitisArmsLevofloxacin Ophthalmic Solution, Moxifloxacin Ophthalmic Solution
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Endogenous panophthalmitis after colonoscopy.Internal and emergency medicine · 2024
    Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

M KerntDepartment of Ophthalmology, Ludwig Maximilian University, Munich, Germany.
A Kampik
Ludwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endophthalmitis is a rare but sight-threatening complication that can occur after ocular surgery or trauma or as a consequence of systemic infection. To optimize visual outcome, early diagnosis and treatment are essential. Over recent decades, advances in hygienic standards, improved microbiologic and surgical techniques, development of powerful antimicrobial drugs, and the introduction of intravitreal antibiotic therapy have led to a decreased incidence and improved management of endophthalmitis. However, endophthalmitis still represents a serious clinical problem. This review focuses on current principles and techniques for evaluation and treatment of endophthalmitis. In addition, it addresses recent developments regarding antimicrobial treatment and prophylaxis of infectious endophthalmitis.

Indexed as

antibioticscaspofunginendophthalmitisintravitrealmoxifloxacinvictrectomyvoriconazole

Identifiers

PMID20390032
PMCPMC2850824
OpenAlexW2026104046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.